comparemela.com

Latest Breaking News On - Breast cancer seventh international consensus conference - Page 1 : comparemela.com

Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer

Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer

THURSDAY, Nov. 16, 2023 (HealthDay News) For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast Cancer Seventh International Consensus Conference, held from Nov. 9 to 11 in Lisbon, Portugal. Binghe Xu, M.D., from

War and prejudice: the problems faced by patients with advanced breast cancer in accessing appropriate treatments

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.